Moderna said Monday it will request emergency clearance from the Food and Drug Administration
for its coronavirus vaccine after new data confirms the vaccine is more than 94% effective in preventing Covid-19 and was safe.
Moderna is the second drugmaker to seek emergency use from the FDA after Pfizer,
another front-runner in the Covid-19 vaccine race, applied for the same authorization on Nov. 20.
The announcement means some Americans could get the first doses of Moderna’s two-dose vaccine within a few weeks.
The new analysis from Moderna evaluated 196 confirmed Covid infections among the late-tage trial’s 30,000 participants.
The company said 185 cases of Covid were observed in the placebo group versus 11 cases observed in the group
that received its vaccine.
That resulted in an estimated vaccine efficacy of 94.1%, the company said.
https://www.cnbc.com/2020/11/30/moderna-covid-vaccine-is-94point1percent-effective-plans-to-apply-for-emergency-ok-monday.html
Moderna says new data shows CovidVaccine is more than 94%effective,plans to ask FDA for emergency clearance later Monday
for its coronavirus vaccine after new data confirms the vaccine is more than 94% effective in preventing Covid-19 and was safe.
Moderna is the second drugmaker to seek emergency use from the FDA after Pfizer,
another front-runner in the Covid-19 vaccine race, applied for the same authorization on Nov. 20.
The announcement means some Americans could get the first doses of Moderna’s two-dose vaccine within a few weeks.
The new analysis from Moderna evaluated 196 confirmed Covid infections among the late-tage trial’s 30,000 participants.
The company said 185 cases of Covid were observed in the placebo group versus 11 cases observed in the group
that received its vaccine.
That resulted in an estimated vaccine efficacy of 94.1%, the company said.
https://www.cnbc.com/2020/11/30/moderna-covid-vaccine-is-94point1percent-effective-plans-to-apply-for-emergency-ok-monday.html